An interventional study of NIDCAP Developmental Care in Cardiology, Infant Development and Development Delay, sponsored by Boston Children's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged Up to 4 Months. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Learning Disabilities with a site in United States — 20 open to participants now, 26 under way, none of them phase 3. Learning Disabilities · United States.
Among the 105 studies in Learning Disabilities with a site in United States, this one is the 46th largest by enrollment of the 71 interventional ones that give a count, is one of 8 that started in 2023, is one of 58 with no phase, reaches primary completion later than 8 of the 24 other live ones, and was the 88th registered.
272 studies on the registry are indexed under Learning Disabilities; 64 are open to participants now.
Browse Learning Disabilities studies →20 of the 105 studies in Learning Disabilities with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 6 mo+
University of Iowa · Sites in United States
Ages 0–50 · Healthy volunteers
University of Nevada, Las Vegas · Sites in United States
Ages 0 mo–5 yrs · Healthy volunteers
IDeA States Pediatric Clinical Trials Network · Sites in United States
Ages up to 7 days · Healthy volunteers
University of Missouri-Columbia · Sites in United States
Ages 0–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Learning Disabilities studies recruiting now, 14 (33%) set no upper age limit and 28 (65%) stop at 75 or younger; 38 take children under 18; 16 take healthy volunteers.
This study: Up to 4 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 4 3
First in 1995; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 60 across 182 interventional studies indexed under Learning Disabilities.
Median enrollment 50 across the 71 interventional studies, 299 across the 34 observational. Of the 71 that completed or were terminated, 19 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 105 have an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 1 study filed under Learning Disabilities — fewer than ten, so there is no comparison to draw.
9 of the studies in Learning Disabilities with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
| NCT02964884Vanderbilt UniversityInterventions for Reading Disabilities in NF1 | 2027-01 |
| NCT05885113Boston Children's HospitalDevelopmental Intervention for Hospitalized Newborns With Congenital Heart Disease | 2027-02-01 |
| NCT03718936Icahn School of Medicine at Mount SinaiADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures. | 2027-03 |
| NCT06771284University of Nevada, Las VegasProblem Behavior Assessment and Intervention in IDEA Part C Services | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 105 studies in Learning Disabilities with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed study includes a newborn developmental intervention to improve neurodevelopmental (ND) and medical outcomes for infants with congenital heart disease (CHD) with improved parent well-being. Literature documents long-term ND disabilities for children with CHD, caused by the negative effects of the hospital environment on the developing newborn brain. The cardiac intensive care unit (CICU), while necessary to save the life of the infant with CHD, exposes infants to overwhelming stress through painful procedures, invasive lines and tubes, toxic sensory stimulation, and separation from family. The combination of these negative experiences disrupts the infant's brain maturation and subsequent neurodevelopment. Individualized developmental care (IDC) is an intervention that minimizes the mismatch between infant neurobiological needs and the harsh hospital environment, thereby diminishing the frequency and severity of adverse effects. Core components of IDC include support for parent engagement, caregiving provided in a way to reduce infant stress, providing a soothing environment and appropriately positioning to enhance musculoskeletal and motor development. Research shows that IDC improves outcomes for preterm infants with enhanced brain structure and function, cognitive skills, executive functioning, behavioral outcomes, and family satisfaction from infancy to school age. Despite all the positive evidence for IDC, my past research showed most CICUs do not implement IDC due to lack of staff education and no evidence supporting IDC in CHD.
The investigators propose the first randomized controlled trial to evaluate the efficacy of IDR as an intervention for children with CHD. The investigators hypothesize infants receiving IDC provided in the hospital, compared to those not receiving IDC, will show improved medical outcomes (including shorter hospital stay, improved oral feeding, increased growth), improved developmental competence, and increased parent coping at the time of discharge home and 3 months after discharge. With support from the Children's Heart Foundation, the investigators can demonstrate the feasibility and safety of implementing IDC in the CICU, the potential to improve the ND outcome for infants with CHD and increase parent well-being. This study would serve as the needed pilot study to request funding for a larger multicenter trial which would impact CICU care of infants with CHD and their families around the world.
Neurodevelopmental (ND) disabilities are the most common, and arguably the most distressing, long-term morbidity in survivors of critical congenital heart disease (CHD).1 As mortality rates for infants with CHD have declined, the need to optimize neurological and ND outcomes in survivors has assumed ever-greater importance. A myriad of studies document that longer ICU and hospital length of stay (LOS) after newborn surgery are among the strongest independent risk factors for ND delay, even after adjusting for known complications and patient factors. Few rigorous studies, however, have thoroughly tested the efficacy of bedside interventions to improve neurodevelopmental outcomes by reducing the environmental toxicities for newborns in the Cardiac Intensive Care Unit (CICU) and other in-patient settings. Individualized Developmental Care (IDC) is an intervention that maximizes the infant neurobiological needs and minimizes the harsh hospital environment, thereby diminishing the frequency and severity of adverse effects and improves long-term developmental outcomes. Core components of IDC include support and education for the family at the bedside on how to care for an ill infant, acknowledging family as the primary caregiver, incorporation of family into hands on care and positive touch, medical caregiving that reduces infant stress and supports the infant throughout, and providing a soothing environment to promote healing, growth and learning. The Newborn Individualized Developmental Care and Assessment Program (NIDCAP)2, 3 is the only evidence-based, comprehensive, internationally recognized program of IDC. IDC in the NIDCAP model has been shown to improve outcomes for premature infants with enhanced brain structure and function, along with improved behavioral outcomes that endure beyond infancy and into school age. In addition, many NIDCAP studies report benefits for medical outcomes such as decreased length of ICU and of hospital stay, earlier oral feeding, and increased weight gain.4-11 IDC as a developmental care intervention is novel in the CHD population, i.e., it has not been routinely used or tested in newborns with CHD. There is a critical need to translate this effective intervention of IDC into policy and routine care service for all infants and children hospitalized, especially those with CHD. This study supports the recent outreach to improve the implementation of effective interventions identified as a priority of health care systems and research agencies internationally.12
The proposed study would thus be the first to test the feasibility of IDC as a hospital intervention for very high-risk newborns with CHD. In this pilot single-center, single blind, before-and-after feasibility study, the investigators will compare two types of experience, standard newborn care (SOC) and the newborn intervention of developmental care (IDC) strictly following the NIDCAP model of care in the cardiology inpatient unit. The investigators will focus on the process of implementing NIDCAP care in cardiology. Following this feasibility study, the researchers will then identify strategies to address the noted challenges and/or revise components of the intervention prior to designing a multisite study to more formally evaluate the NIDCAP intervention in cardiology. Specific aims are as follows:
Primary Aim: To describe feasibility for providing IDC for infants with CHD while inpatient in cardiology. The investigators will describe organizational/contextual factors, which influence future implementation trial methods, such as recruitment, retention, data collection procedures, implementation of study protocol, and any safety concerns.
Hypothesis 1: IDC will be feasible to implement in the CICU and the cardiology step down unit/ Acute Cardiology Care Unit (ACCU). Infants who receive the IDC intervention will show an appropriate level (score of 3.5 or higher) of developmental care at the bedside during caregiving on the measure of developmental care (NIDCAP Organizational Structures Assessment13 (OSA)) scored by a study observer blind to study group. The IDC group infants will have higher scores on the OSA measurement of developmental care at the bedside than the SOC group infants.
Hypothesis 2: It will be possible to recruit enough patients into the study over the two year time frame. The investigators will collect the number of patients eligible for the study, number approached for the study, the number consented, and those that discontinue or drop from the study, along with reasoning for why someone did not meet criteria or choose to leave the study. .
Hypothesis 3: There will be no safety concerns as reported by the Safety Event Reporting System (SERS) in connection with this NIDCAP study. The investigators will review each month the number of SERS reported in the CICU and ACCU related to the study.
Secondary Aims
To describe the feasibility of collecting the developmental outcome assessments in this cardiac population.
Hypothesis 1: It will be feasible to collect the Neonatal Network Neurobehavioral Scale II (NNNS) and the Developmental Assessment of Young Children-Second Edition (DAYC-2) on this population of infants. The number of missing variables will be assessed.
Hypothesis 1: Infants in the intervention group (IDC), receiving NIDCAP care will have parents who are more engaged at the bedside with higher scores (indicated increased engagement) on the Parent Risk Evaluation and Engagement Model Instrument (PREEMI) than parents of infants receiving SOC.
Hypothesis 2: Due to the increased attention to parent infant interaction given through the NIDCAP intervention, parents in the IDC group will report more time at the bedside and more daily interaction with their child on the daily diary of care than parents in the SOC group.
Our feasibility trial will provide the first, urgently needed, proof-of-concept that IDC can be implemented in hospitalized critically ill newborns with CHD. When proven to be successful, this study will provide information vital to funding of a multicenter randomized trial further expanding the knowledge of IDC for infants with CHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NIDCAP developmental care group receiving intervention
Behavioral: NIDCAP Developmental Care
NO intervention, control group, receiving standard of care
The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
Also known as: NIDCAP, Individualized Developmental Care
NIDCAP Organizational Structures Assessment (OSA))
Measure of Developmental Care in the hospital at the bedside; 0-5 with 5 being the best score.
Time frame: up to 2 months of age
Neonatal Network Neurobehavioral Scale II (NNNS) of Young Children-Second Edition (DAYC-2)
infant assessment; summary scores in percentile; 10-90 percentiles are considered normative performance.
Time frame: up to 2 months of age
Developmental Assessment of Young Children-Second Edition (DAYC-2)
infant assessment; standard score with 100 average and S.D. of 15.
Time frame: at 3 months of age
Plan to share: No
Started Oct 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.
Of 97 non-industry interventional studies with no phase under Learning Disabilities, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 53. This study's planned 39 months is above that.
Counting every sponsor, half of 100 studies reached it within 29 months; a quarter within 9 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.